The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis.

Autor: Culpepper L; Department of Family Medicine, Boston University School of Medicine, 90 Sylvia Ln, Westport, MA, 02790-1406, USA. laculpep@bu.edu., Martin A; Health Economics and Outcomes Research, Cerner Enviza, New York, NY, USA., Nabulsi N; Health Economics and Outcomes Research, AbbVie, North Chicago, IL, USA., Parikh M; Health Economics and Outcomes Research, AbbVie, Florham Park, NJ, USA.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 May; Vol. 41 (5), pp. 1860-1884. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1007/s12325-024-02817-w
Abstrakt: Introduction: Major depressive disorder (MDD) is a debilitating and costly condition. This analysis characterized the health-related quality of life (HRQoL), health care resource utilization (HCRU), and costs between patients with versus without MDD, and across MDD severity levels.
Methods: The 2019 National Health and Wellness Survey was used to identify adults with MDD, who were stratified by disease severity (minimal/mild, moderate, moderately severe, severe), and those without MDD. Outcomes included HRQoL (Short Form-36v2 Health Survey, EuroQol Five-Dimension Visual Analogue Scale, utility scores), HCRU (hospitalizations, emergency department [ED] visits, health care provider [HCP] visits), and annualized average direct medical and indirect (workplace) costs. A subgroup analysis was conducted in participants with MDD and prior medication treatment failure. Participant characteristics and study outcomes were evaluated using bivariate analyses and multivariable regression models, respectively.
Results: Cohorts comprised 10,710 participants with MDD (minimal/mild = 5905; moderate = 2206; moderately severe = 1565; severe = 1034) and 52,687 participants without MDD. Participants with MDD had significantly lower HRQoL scores than those without (each comparison, P < 0.001). Increasing MDD severity was associated with decreasing HRQoL. Relative to participants without MDD, participants with MDD reported more HCP visits (2.72 vs 5.64; P < 0.001) and ED visits (0.18 vs 0.22; P < 0.001) but a similar number of hospitalizations. HCRU increased with increasing MDD severity. Although most patients with MDD had minimal/mild to moderate severity, total direct medical and indirect costs were significantly higher for participants with versus without MDD ($8814 vs $6072 and $5425 vs $3085, respectively, both P < 0.001). Direct and indirect costs were significantly higher across all severity levels versus minimal/mild MDD (each comparison, P < 0.05). Among patients with prior MDD medication treatment failure (n = 1077), increasing severity was associated with significantly lower HRQoL and higher total indirect costs than minimal/mild MDD.
Conclusion: These results quantify the significant and diverse burdens associated with MDD and prior MDD medication treatment failure.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: